Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

Ohio State University Comprehensive Cancer Center

     
Columbus , OH 43210
USA

 

Principal Investigator:
 James L. Chen
Contact:
 Site Public Contact: 800-293-5066 Jamesline@osumc.edu
Activation Status of this Site:
 Closed
Notes about this Site:
Ohio State University Comprehensive Cancer Center Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.